Rani Therapeutics Holdings, Inc. financial data

Symbol
RANI on Nasdaq
Industry
Pharmaceutical Preparations
Location
2051 Ringwood Avenue, San Jose, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 31, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 193 % -81.9%
Debt-to-equity 965 % +495%
Return On Equity -409 % -412%
Return On Assets -67.7 % -53.6%

Shares

Label TTM Value / Value Unit Change %
Entity Public Float 51.9M USD -4.07%
Weighted Average Number of Shares Outstanding, Basic 28.5M shares +11.6%
Weighted Average Number of Shares Outstanding, Diluted 28.5M shares +11.6%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 26.7M USD -32.7%
General and Administrative Expense 23.9M USD -9.55%
Operating Income (Loss) -53.3M USD +19.3%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -67.9M USD -7.28%
Income Tax Expense (Benefit) 0 USD -100%
Net Income (Loss) Attributable to Parent -30M USD +11.6%
Earnings Per Share, Basic -1.05 USD/shares +21.1%
Earnings Per Share, Diluted -1.05 USD/shares +21.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 3.76M USD -35.8%
Assets, Current 29.7M USD -41.5%
Property, Plant and Equipment, Net 1.55M USD -74.6%
Operating Lease, Right-of-Use Asset 5.1M USD +610%
Other Assets, Noncurrent 246K USD 0%
Assets 36.6M USD -36.7%
Accounts Payable, Current 1.36M USD +110%
Liabilities, Current 19.9M USD +149%
Operating Lease, Liability, Noncurrent 3.64M USD
Liabilities 33.1M USD +2.06%
Accumulated Other Comprehensive Income (Loss), Net of Tax 5K USD
Retained Earnings (Accumulated Deficit) -103M USD -41.2%
Stockholders' Equity Attributable to Parent 1.99M USD -84.5%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 3.49M USD -86.3%
Liabilities and Equity 36.6M USD -36.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -9.4M USD +22.6%
Net Cash Provided by (Used in) Financing Activities 121K USD -98.5%
Net Cash Provided by (Used in) Investing Activities 10.3M USD +150%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 1.01M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 4.26M USD -33%
Deferred Tax Assets, Valuation Allowance 69.1M USD +13.2%
Deferred Tax Assets, Gross 69.1M USD +13.2%
Operating Lease, Liability 5.1M USD +610%
Payments to Acquire Property, Plant, and Equipment 18K USD -92.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -30M USD +11.5%
Lessee, Operating Lease, Liability, to be Paid 6.2M USD +727%
Property, Plant and Equipment, Gross 5.87M USD +31.3%
Operating Lease, Liability, Current 1.46M USD +103%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.23M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 1.9M USD +154%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.1M USD +3452%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.28M USD
Deferred Tax Assets, Operating Loss Carryforwards 19.4M USD +49.3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 20M shares 0%
Unrecognized Tax Benefits 661K USD +35.2%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.33M USD
Operating Lease, Payments 180K USD -30.5%
Additional Paid in Capital 105M USD +22.3%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Interest Expense 5.03M USD -1.02%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%